U.S. Securities and Exchange Commission
                             Washington, D.C. 20549

                                   Form 10-QSB

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE  SECURITIES
EXCHANGE ACT OF 1934

For the quarter ended: March 31, 2001

Commission file no.:  000-31889

                               Bio-One Corporation
                  --------------------------------------------
                 (Name of small business issuer in its charter)

             Nevada                                         65-0815746
-------------------------------                        -----------------------
(State or other jurisdiction of                              (I.R.S. Employer
incorporation or organization)                             Identification No.)

310 Waymont Court, Suite 100
Lake Mary, Florida                                             32746
------------------------------------------                 -----------------
(Address of principal executive offices)                     (Zip Code)

Issuer's telephone number (407) 328-1611

Securities registered under Section 12(b) of the Exchange Act:

                                                 Name of each exchange on
      Title of each class                        which registered

                None                                    None
-----------------------------                    -------------------------

Securities registered under Section 12(g) of the Exchange Act:

                         Common Stock, $0.001 par value
                       -----------------------------------
                                (Title of class)

Copies of Communications Sent to:
                                       Mintmire & Associates
                                       265 Sunrise Avenue, Suite 204
                                       Palm Beach, FL 33480
                                       Tel: (561) 832-5696
                                       Fax: (561) 659-5371


<PAGE>



     Indicate by Check  whether the issuer (1) filed all reports  required to be
filed by Section 13 or 15(d) of the  Exchange  Act during the past 12 months (or
for such shorter  period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.

                  Yes  X        No
                       ---          ----

     As of March 31, 2001,  there were 10,010,999  shares of voting stock of the
registrant issued and outstanding.



<PAGE>



                                     PART I

Item 1. Financial Statements



<TABLE>
<CAPTION>
                               BIO-ONE CORPORATION

                                      Index

                                                                               Page Number

<S>                                                                             <C>
  Balance Sheets March 31, 2001 (Unaudited) and December 31, 2000               F-3

  Statements of Operations Three months ended March 31, 2001 (Unaudited) and
  March 31, 2000 (Unaudited)                                                    F-5

  Statements of Cash Flows Three months ended March 31, 2001 (Unaudited) and
  March 31, 2000 (Unaudited)                                                    F-6

  Notes to Financial Statements (Unaudited)                                     F-7
</TABLE>







<PAGE>



<TABLE>
<CAPTION>
                               BIO-ONE CORPORATION

                                 Balance Sheets



              Assets
                                                                  December 31,      March 31, 2001
                                                                      2000            (Unaudited)
                                                                  ---------------   ---------------
<S>                                                               <C>               <C>
Current assets:
     Cash and cash equivalents                                    $        19,832   $        37,683
     Accounts receivable                                                    1,930             1,689
     Inventories                                                           19,901            16,870
                                                                  ---------------   ---------------

              Total current assets                                         41,663            56,242


Property and equipment, at cost, net of accumulated
depreciation and amortization                                              14,906            24,919

     Deposits                                                               1,700             1,700
                                                                  ---------------   ---------------

              Total assets                                        $        58,269   $        82,861
                                                                  ===============   ===============
</TABLE>

                 See accompanying notes to financial statements.








                                       F-3

<PAGE>



<TABLE>
<CAPTION>
                               BIO-ONE CORPORATION

                                 Balance Sheets



              Liabilities and Shareholders' Equity
                                                                  December 31,      March 31, 2001
                                                                      2000            (Unaudited)
                                                                  ---------------   ---------------
<S>                                                               <C>               <C>

Current liabilities:
     Accounts payable                                             $        30,160   $       26,948
     Accrued expenses                                                     203,468          229,468
     Current installments of note payable                                 124,502           99,502
                                                                  ---------------   --------------

              Total current liabilities                                   358,130          355,918
                                                                  ---------------   --------------


Shareholders' equity:
Common stock - $.001 par value, authorized 100 million
        shares; issued 9,844,999 and 10,344,999 shares                      9,845           10,345
     Additional paid in capital                                           279,255          403,755
     Accumulated deficit                                                 (588,961)        (687,157)
                                                                  ---------------   --------------

              Total shareholders' equity                                 (299,861)        (273,057)
                                                                  ---------------   --------------

                                                                  $        58,269   $       82,861
                                                                  ===============   ==============
</TABLE>

                See accompanying notes to financial statements.





                                       F-4

<PAGE>



<TABLE>
<CAPTION>
                               BIO-ONE CORPORATION

                            Statements of Operations

                                                                         Three Months Ended
                                                                             March 31,
                                                                   2000                      2001
                                                               (Unaudited)               (Unaudited)
                                                           --------------------      --------------------
<S>                                                         <C>                       <C>
Revenues:
     Net sales                                              $                 -       $            12,790
     Consulting fees                                                     18,958                         -
                                                           --------------------      --------------------

                                                                         18,958                    12,790
Costs and expenses:
     Cost of goods sold                                                       -                     6,884
     Selling, general and administrative                                 41,960                   100,333
                                                           --------------------      --------------------

                                                                         41,960                   107,217
                                                           --------------------      --------------------

              Operating income (loss)                                   (23,002)                  (94,427)

Non-operating revenue (expense):
     Interest expense                                                           -                  (3,769)
                                                           --------------------      --------------------

              Income before income taxes                                (23,002)                  (98,196)

Provision for income taxes                                                    -                         -
                                                           --------------------      --------------------

              Net income                                    $           (23,002)      $           (98,196)
                                                           ====================      ====================

Basic earnings per share                                    $                 -       $             (0.02)
                                                           ====================      ====================

Diluted earnings per share                                  $                 -       $             (0.02)
                                                           ====================      ====================

Weighted average number of shares outstanding                         4,994,500                 6,482,900
                                                           ====================      ====================
</TABLE>


                 See accompanying notes to financial statements.



                                       F-5

<PAGE>





<TABLE>
<CAPTION>
                               BIO-ONE CORPORATION

                            Statements of Cash Flows

                                                                               Three Months Ended
                                                                                    March 31,
                                                                           2000                2001
                                                                        (Unaudited)        (Unaudited)
                                                                     ------------------  ------------------
<S>                                                                   <C>                 <C>
Cash flows from operating activities:
    Net loss                                                          $         (23,002)  $         (98,196)
Adjustments to reconcile net income to net cash
        provide by operating activities:
           Depreciation and amortization                                            600               1,000
           Changes in operating assets and liabilities:
              Accounts receivable                                                (2,098)                241
              Inventories                                                        (4,952)              3,031
              Accounts payable and accrued expenses                                 353              22,788
                                                                     ------------------  ------------------

                   Net cash used in operating activities                        (29,099)            (71,136)
                                                                     ------------------  ------------------

Cash flows from investing activities:
    Purchase of property and equipment                                             (600)            (11,013)
                                                                     ------------------  ------------------

                   Net cash used in investing activities                           (600)            (11,013)
                                                                     ------------------  ------------------

Cash flows from financing activities:
    Proceeds from sale of common stock                                           39,000             125,000
    Payment of principal on note payable                                              -             (25,000)
    Proceeds from note payable                                                    4,500                   -
                                                                     ------------------  ------------------

                   Net cash provided by financing activities                     43,500             100,000
                                                                     ------------------  ------------------

                   Increase in cash and cash equivalents                         13,801              17,851

Cash and cash equivalents - beginning of period                                      70             19,832
                                                                     ------------------  ------------------

Cash and cash equivalents - end of period                            $           13,871  $           37,683
                                                                     ==================  ==================
</TABLE>

                 See accompanying notes to financial statements.



                                       F-6

<PAGE>


                               BIO-ONE CORPORATION

Notes to Financial Statements


(1)      Presentation of Unaudited Financial Statements

The unaudited  financial  statements have been prepared in accordance with rules
of the Securities and Exchange  Commission  and,  therefore,  do not include all
information  and  footnotes  necessary  for a  fair  presentation  of  financial
position,  results of operations  and cash flows,  in conformity  with generally
accepted accounting  principles.  The information  furnished,  in the opinion of
management,  reflects  all  adjustments  (consisting  only of  normal  recurring
accruals)  necessary to present  fairly the  financial  position as of March 31,
2001, and results of operations and cash flows for the three month periods ended
March  31,  2001  and  2000.  The  results  of  operations  are not  necessarily
indicative of results which may be expected for any other interim period, or for
the year as a whole.

(2)      Sales to Major Customers

During the three months ended March 31, 2001, one customer accounted for 76% of
total revenue.

(3)      Inventories

Inventories consist of the following:


                        December 31,       March 31, 2001
                            2000            (Unaudited)
                        ------------       ------------

Finished goods             $  19,901             16,870
                        ============       ============







                                       F-7


<PAGE>



Item 2. Management's Discussion and Analysis of Results of Operations.

General

     In March 2001,  the Company sold  400,000 and 100,000  shares of its common
stock to John M.  Moxen  and Ohio Well  Management,  Inc.,  an Ohio  corporation
respectively for a total of $125,000. The Company issued warrants to purchase an
additional  500,000 shares of the Company's common stock at an exercise price of
$1.00 per share or eighty  percent  (80%) of the average bid price for the first
three (3) weeks of public  trading,  whichever  is lower.  The  warrants  expire
twelve (12) months from the date on which the Company's common stock is approved
for quotation on the Over the Counter  Bulletin  Board.  For such offering,  the
Company  relied upon Section 4(2) of the Securities Act of 1933, as amended (the
"Act"),  Rule 506 of Regulation D promulgated  thereunder ("Rule 506"),  Section
517.061(11) of the Florida Code and Section 1707.03(X) of the Ohio Code.

     The facts relied upon to make the Florida Exemption  applicable include the
following: (i) sales of the shares of common stock were not made to more than 35
persons;  (ii)  neither  the  offer  nor  the  sale  of any of  the  shares  was
accomplished  by the  publication  of any  advertisement;  (iii) all  purchasers
either had a preexisting  personal or business  relationship with one or more of
the  executive  officers  of the  Company  or, by reason  of their  business  or
financial  experience,  could be  reasonably  assumed  to have the  capacity  to
protect  their own  interests  in  connection  with the  transaction;  (iv) each
purchaser  represented that he was purchasing for his own account and not with a
view to or for sale in connection with any  distribution of the shares;  and (v)
prior to sale,  each  purchaser  had  reasonable  access to or was furnished all
material books and records of the Company,  all material contracts and documents
relating to the proposed  transaction,  and had an  opportunity  to question the
executive  officers of the Company.  Pursuant to Rule  3E-500.005,  in offerings
made under Section  517.061(11) of the Florida Statutes,  an offering memorandum
is not required; however each purchaser (or his representative) must be provided
with or  given  reasonable  access  to full  and  fair  disclosure  of  material
information.  An  issuer  is deemed to be  satisfied  if such  purchaser  or his
representative  has been given access to all  material  books and records of the
issuer;   all  material   contracts  and  documents  relating  to  the  proposed
transaction;  and an opportunity to question the appropriate  executive officer.
In the regard,  the Company supplied such information and was available for such
questioning.

     The facts  relied  upon to make the Ohio  Exemption  available  include the
following:  (i) the Company  filed a completed SEC Form D with the Ohio Division
of  Securities;  (ii) the  Company  executed  a Form U-2  consent  to service of
process in the state of Ohio;  (iii) the forms were filed not later than fifteen
(15) days after the first sale of the  securities in Ohio;  and (iv) the Company
paid an appropriate filing fee of $100.

     In April 2001, the Company issued 10,000 shares of its common stock to Curt
Jones, who served as a financial  consultant to the Company.  For such offering,
the  Company  relied  upon  Section  4(2)  of the  Act,  Rule  506  and  Section
517.061(11) of the Florida Code.

     The facts relied upon to make the Florida Exemption  applicable include the
following: (i) sales of the shares of common stock were not made to more than 35
persons;  (ii)  neither  the  offer  nor  the  sale  of any of  the  shares  was
accomplished  by the  publication  of any  advertisement;  (iii) all  purchasers
either had a preexisting  personal or business  relationship with one or more of
the  executive  officers  of the  Company  or, by reason  of their  business  or
financial experience, could be


<PAGE>



reasonably  assumed to have the  capacity  to  protect  their own  interests  in
connection with the  transaction;  (iv) each purchaser  represented  that he was
purchasing  for his own account and not with a view to or for sale in connection
with any  distribution of the shares;  and (v) prior to sale, each purchaser had
reasonable  access to or was  furnished  all  material  books and records of the
Company,   all  material  contracts  and  documents  relating  to  the  proposed
transaction,  and had an opportunity  to question the executive  officers of the
Company.   Pursuant  to  Rule  3E-500.005,   in  offerings  made  under  Section
517.061(11)  of the Florida  Statutes,  an offering  memorandum is not required;
however each  purchaser (or his  representative)  must be provided with or given
reasonable access to full and fair disclosure of material information. An issuer
is deemed to be satisfied if such purchaser or his representative has been given
access to all material books and records of the issuer;  all material  contracts
and  documents  relating to the  proposed  transaction;  and an  opportunity  to
question the appropriate  executive officer. In the regard, the Company supplied
such information and was available for such questioning.

     The Company has an ongoing private  offering of its common stock at a price
of $0.25 per share.  Investors  also  receive a warrant to  purchase  additional
shares at a price of $1.00 per share or a twenty  percent (20%)  discount of the
average bid price for the first three (3) weeks of public trading,  whichever is
lower.  The  warrants  expire  twelve  (12)  months  from the date on which  the
Company's  common  stock is  approved  for  quotation  on the  Over the  Counter
Bulletin  Board.  Thus far the Company has relied upon  Section 4(2) of the Act,
Rule 506 and applicable state exemptions for such offering.  The Company has not
utilized a memorandum in connection with this offering.

Discussion and Analysis

     The following  discussion and analysis  should be read in conjunction  with
the financial  statements of the Company and the  accompanying  notes  appearing
subsequently under the caption "Financial  Statements." The following discussion
and  analysis  contains  forward-looking  statements,  which  involve  risks and
uncertainties in the  forward-looking  statements.  The Company's actual results
may differ  significantly from the results,  expectations and plans discussed in
the forward- looking statements.

     The Company's  growth is expected to come  primarily from the private label
manufacture and wholesale  distribution  of human and animal health  supplements
and supply of ingredients (nutraceutical based health supplements) for inclusion
in health  supplements and foods.  This pattern of growth will closely correlate
to increases in the Company's health  supplement  manufacturing and distribution
capacity and its development of proprietary health supplement technologies.

     On May 30, 2000, the Company acquired the assets of Crown Enterprises, Inc.
By purchasing  the assets of Crown,  a "cottage"  private label  distributor  of
health   supplements,   the  Company  acquired   technology  and  a  proprietary
nutritional  supplements  product  line.  The  operation  produced  only nominal
revenues in 1999.  Operations for private label  manufacturing  and distribution
are  expected  to begin  after  assembling  a staff  experienced  in the  health
supplement  industry  and after  raising  the funds  necessary  to  purchase  an
existing  manufacturing  facility.  Company management estimates that $2 million
will be needed to purchase such  facility.  The monies needed are expected to be
raised by the  Company  through  private  placement  efforts  to the  investment
community. No funding source has yet been identified.  Additionally, no specific
facility has been selected by the Company for purchase.



<PAGE>



     In addition to private label distribution, the Company also benefitted from
its development of its Live Blood Cell Analysis  program the second half of 1999
and first half of 2000.  The  Company  conducted  extensive  experimentation  to
develop the trademarked  GREEN  PEARLS(TM)  product line and the process for the
capsuling of BLUE GREEN ALGAE FROM UPPER LAKE KLAMATH with extended  shelf-life.
GREEN  PEARLS(TM) is a unique  natural food source,  which is a standard  health
food supplement for maintaining  individual health. By mid-1999, the Company had
perfected  a  process  for  producing  GREEN  PEARLS(TM)  with  a two  (2)  year
shelf-life.  The  Company  began  distribution  of GREEN  PEARLS(TM)  to several
customers in the second quarter of 1999.

     Since acquiring  Crown,  the Company has begun to make  preparations  for a
period of growth,  which may require it to  significantly  increase the scale of
its operations. This increase will include the hiring of additional personnel in
all functional areas and will result in significantly higher operating expenses.
The  increase in  operating  expenses is expected to be matched by a  concurrent
increase in revenues.  However,  the  Company's  net loss may  continue  even if
revenues  increase  and  operating  expenses  may still  continue  to  increase.
Expansion of the  Company's  operations  may cause a  significant  strain on the
Company's  management,  financial and other resources.  The Company's ability to
manage recent and any possible future growth,  should it occur, will depend upon
a significant  expansion of its accounting and other internal management systems
and the  implementation  and  subsequent  improvement  of a variety of  systems,
procedures and controls.  There can be no assurance that significant problems in
these areas will not occur.  Any failure to expand these areas and implement and
improve such systems,  procedures and controls in an efficient  manner at a pace
consistent with the Company's  business could have a material  adverse effect on
the Company's  business,  financial  condition and results of  operations.  As a
result of such expected expansion and the anticipated  increase in its operating
expenses,  as well as the difficulty in forecasting  revenue levels, the Company
expects to continue to  experience  significant  fluctuations  in its  revenues,
costs and gross margins, and therefore its results of operations.

Results of Operations  -For the Three Months Ending March 31, 2001 and March 31,
2000

Financial Condition, Capital Resources and Liquidity

     Through the 1st quarter ended March 31, 2001 the Company recorded  revenues
of $12,790.  For the 1st quarter  ended March 31, 2000 the Company had  selling,
general and administrative  expenses and total operating expenses of $41,960 and
$41,960  respectively.  For the 1st quarter ended March 31, 2001 the Company had
selling,  general and  administrative  expenses and total operating  expenses of
$100,333 and $107,217 respectively. This increase of $58,373 and $65,257 was due
to  employment  contract  fees accrued for the  Company's  management as well as
legal and  accounting  expenses  associated  with the  filing  of the  Company's
Registration Statement on Form 10SB with the SEC.

Net Losses

     Through  the 1st quarter  ended  March 31, 2000 the Company  reported a net
loss of  $23,002.  Through  the 1st  quarter  ended  March 31,  2001 the Company
reported a net loss of  $94,427.  The  increased  loss is  primarily  due to the
increased  expenses  described  above  and  an  anticipated  large  sale  of the
Company's  products in March that did not actually  occur until after the fiscal
quarter ended in April.



<PAGE>



     The ability of the Company to continue as a going concern is dependent upon
increasing sales and obtaining additional capital and financing.  The Company is
currently seeking financing to allow it to continue its planned operations.

Employees

     At March 31, 2001,  the Company  employed  two (2)  persons.  None of these
employees  are   represented  by  a  labor  union  for  purposes  of  collective
bargaining.  The  Company  considers  its  relations  with its  employees  to be
excellent.  The  Company  plans to employ  additional  personnel  as needed upon
product rollout to accommodate fulfillment needs.

Research and Development

     Health Supplement  Development:  The Company develops products requested by
customers,  and/or develops new product concepts which it licenses to customers.
The Company also  actively  seeks and reviews new  nutraceutical  materials  and
delivery  technologies  developed  by  independent  researchers.   There  is  no
assurance  that this research and  development  effort will result in marketable
products or services.

Forward-Looking Statements

     This Form 10-QSB includes  "forward-looking  statements" within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities  Exchange  Act of  1934,  as  amended.  All  statements,  other  than
statements of historical  facts,  included or  incorporated by reference in this
Form 10-QSB which address  activities,  events or developments which the Company
expects or anticipates will or may occur in the future, including such things as
future capital expenditures (including the amount and nature thereof), expansion
and growth of the Company's business and operations,  and other such matters are
forward-looking  statements.  These statements are based on certain  assumptions
and analyses made by the Company in light of its  experience  and its perception
of historical  trends,  current  conditions and expected future  developments as
well as other factors it believes are appropriate in the circumstances. However,
whether  actual  results  or  developments   will  conform  with  the  Company's
expectations and predictions is subject to a number of risks and  uncertainties,
general economic market and business conditions;  the business opportunities (or
lack  thereof)  that may be presented to and pursued by the Company;  changes in
laws or regulation;  and other factors,  most of which are beyond the control of
the Company.

     Consequently,  all of the  forward-looking  statements  made in  this  Form
10-QSB  are  qualified  by  these  cautionary  statements  and  there  can be no
assurance  that the actual  results or  developments  anticipated by the Company
will be realized  or, even if  substantially  realized,  that they will have the
expected consequence to or effects on the Company or its business or operations.

PART II

Item 1.  Legal Proceedings.

     The  Company  knows  of no legal  proceedings  to which it is a party or to
which any of its  property  is the  subject  which are  pending,  threatened  or
contemplated or any unsatisfied judgments against the Company.


<PAGE>




Item 2. Changes in Securities and Use of Proceeds

         None.

Item 3. Defaults in Senior Securities

         None

Item 4.  Submission of Matters to a Vote of Security Holders.

     No matter was submitted  during the quarter ending March 31, 2001,  covered
by this report to a vote of the Company's shareholders, through the solicitation
of proxies or otherwise.

Item 5. Other Information

         None.

Item 6. Exhibits and Reports on Form 8-K

     (a) The exhibits  required to be filed  herewith by Item 601 of  Regulation
S-B, as described in the following index of exhibits, are incorporated herein by
reference, as follows:

<TABLE>
<CAPTION>
Item 1.           Index to Exhibits

<S>      <C>      <C>
3.(i).1  [1]      Articles of Incorporation of Bio-One Corporation filed February 24, 1998.

3.(i).2  [1]      Certificate of Amendment of Articles of Incorporation increasing authorized capital
                  stock filed August 7, 2000.

3.(ii).1 [1]      Bylaws of Bio-One Corporation

4.1      [1]      Form of Private Placement Offering of 1,600,000 common shares at $0.01 per share.

4.2      [1]      Promissory Note in favor of Kevin Thomas dated August 8, 2000.

4.3      [2]      Convertible Note in favor of Margaret Schrock dated December 5, 2000.

10.1     [1]      Share Exchange Agreement between the Company and Crown Enterprises, Inc. dated
                  May 20, 2000.

10.2     [1]      Employment Agreement between the Company and Armand Dauplaise dated May
                  30, 2000.

10.3     [1]      Employment Agreement between the Company and Kevin Lockhart dated May 30,
                  2000.

10.4     [1]      Lease Agreement between Crown Enterprises and Daniel Jack Co. dated August 15,
                  2000.

10.5     [2]      Removed.
-------------------------------------------------
</TABLE>



<PAGE>




[1]  Incorporated herein by reference to the Company's Registration Statement on
     Form 10-SB filed November 3, 2000.

[2]  Incorporated  herein by reference  to the  Company's  amended  Registration
     Statement on Form 10-SB filed January 5, 2001.

     (b) No reports on Form 8-K have been filed.

Item 2.  Description of Exhibits

     The documents  required to be filed as Exhibits  Number 2 and 6 and in Part
III of Form 1-A filed as part of this  Registration  Statement on Form 10-SB are
listed in Item 1 of this Part III above.  No documents  are required to be filed
as Exhibit  Numbers 3 , 5 or 7 in Part III of Form 1-A and the reference to such
Exhibit  Numbers is therefore  omitted.  The following  additional  exhibits are
filed hereto:









[Balance of this page intentionally left blank.]








<PAGE>



                                   SIGNATURES
                          -----------------------------

     In accordance  with the  requirements  of the Exchange Act, the  registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                               Bio-One Corporation
                    ----------------------------------------
                                  (Registrant)


Date: May 03, 2001     By: /s/ Armand Dauplaise
                       -----------------------------------
                       Armand Dauplaise, President and Chairman


                       By: /s/ Kevin Lockhart
                       -----------------------------------
                       Kevin Lockhart, Secretary


<PAGE>